Bispecifics keep the business development fires burning
Cytomx’s bispecific Probody approach attracts Astellas in a deal with a seemingly high up-front payment.
Tiziana takes a deep breath and targets Covid-19
Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?
Another preclinical thumbs-up for Sangamo’s zinc fingers
The deal between Sangamo and Biogen marks another endorsement of a gene-editing technology that many had written off years ago.
Healx lands $56m to power artificial intelligence-led drug discovery
Healx's "hypothesis-free" approach proves a big draw to investors despite the early-stage nature of the group's projects.
Uncovering biopharma’s hidden treasures
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
Venture cash gets even more concentrated
The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.
As the heat rises, Clovis turns to radionuclides
The beleaguered drug maker has licensed a preclinical FAP-directed radiopharmaceutical, a target that has made little progress.
Bluerock unlikely to smooth Bayer’s rocky road
Bayer has responded to its current woes by going all in on cell therapy – a move that, even if successful, will take a long time to pay off.
Squelgene does a lopsided swap with Jounce
Celgene opts out of Jounce’s Icos agonist ahead of its merger with Bristol-Myers Squibb.
